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Abstract
Background Patients with severe complaints of radiation-
induced ﬁbrosis after breast-conserving therapy and not
responding to conservative therapy, were treated by partial
mastectomy and m. latissimus dorsi reconstruction.
Method To determine the feasibility and outcome of this
approach, a retrospective study of nine patients was carried
out.
Results After a mean follow-up of 46 months, eight of
the nine patients experienced improvement of their com-
plaints and shape of the breast. In only one case did the
procedure fail, as evidenced by continuation of all
complaints.
Conclusions Partial mastectomy and m. latissimus dorsi
reconstruction is the ultimate option in the treatment of
radiation ﬁbrosis. The procedure is safe with satisfying
results.
Introduction
Cancer patients who undergo radiotherapy (RT) remain at
lifelong risk of serious radiation-induced injury to normal
tissue. This injury varies from ﬁbrosis and radionecrosis to
radiation-induced malignancies in the long term. In breast
cancer about half of the patients are treated with breast-
conserving therapy (BCT), and this number seems to be
increasing. A consequence of BCT is that postoperatively
the remaining breast is irradiated, and a boost is given at
the lumpectomy site [1]. These patients have a potential
risk of radiation-related complications.
The complications are radiation dose and fractionation
related, with a critical cut-off point of 50 Gy [2]. Other
individual characteristics, such as diabetes and vascular
disorders can contribute to the complication rate. In most
cases the acute reaction will stay within acceptable limits
and will return to normal within a few weeks. When the
unfavorable effects persist for longer than 6 months,
spontaneous improvement cannot be expected.
The layer of endothelium supplying the irradiated area
starts to proliferate, resulting in a proliferative endarteritis.
Most often noted in the capillaries, the endarteritis con-
tinues and interferes with the normal process of supplying
blood to irradiated areas.
Signiﬁcant problems arise during this clinical period as a
consequence of chronic deterioration of the microvascula-
ture and hypoperfusion, resulting in a mild radiation-
induced ﬁbrosis (RIF) in the boost area. With increasing
tissue ﬁbrosis and parenchymal degeneration, the com-
promised tissue has a lower resistance to stress factors.
The ischemic tissue may survive without adequate blood
supply for a long time, but a traumatic or infectious inci-
dent can trigger a series of events that may ultimately lead
to extensive tissue death.
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underestimating its true incidence [3, 4]. Studies report that
about 45% of patients experience breast pain associated
with RIF, ranging from frequent to constant pain in the
irradiated area [5].
In published series it has been suggested that RIF stabi-
lizes 2 years after RT to the breast [6]. Clinically, RIF is
characterized by skin retraction, atrophy, and toughness to
palpation, with consequent functional limitations, as well as
by decreased tissue compliance. There will be a limited
number of women with a progressive RIF over years; how-
ever, the exact number is unknown
Depending on the patient’s complaints, conservative
treatment can be administered; this can include systemic or
topical medication (corticosteroids, anti-inﬂammatory
agents, zinc, antioxidants), physiotherapy, or hyperbaric
oxygen therapy. However, the results have been disap-
pointing, and reports in the literature provide no evidence of
beneﬁt.
In some cases the RIF will become worse with persisting
severe complaints, such as pain, deformity of the breast,
discoloration, and repeated infections of the overlying skin.
When conservative treatment has failed and complaints
remain,excisionoftheareawithﬁbrosisorevenmastectomy
might be the ultimate treatment option. Excisional proce-
duresoftenhavenumerouscomplications,however,because
the surrounding tissue does not heal due to radiotherapy-
inducedischemia.Whenattemptingtografttoorrotateaﬂap
to this area, surgeons must connect to tissue that is ischemic
and hypoxic. The proper approach to overcoming this
problem is to remove an extensive amount of breast tissue
beyond the boost area, which results in a partial mastectomy
(PM).Oncoplastictechniquescanbeusedtoclosethedefect,
either with tissue displacement or tissue replacement.
The m. latissimus dorsi (LD) reconstruction is a widely
used and safe reconstruction after partial or total mastec-
tomy [7, 8]. In irradiated areas it has also been proven to be
safe [9]. The present study describes patients with serious
complaints of RIF who were treated by a PM with LD
reconstruction.
Patients and methods
In a retrospective study we describe nine patients with
varying complaints after breast-conserving therapy fol-
lowed by radiotherapy. When all conservative treatment
failed, we operated on these patients with a partial mas-
tectomy and reconstruction. The area with RIF was widely
excised by a partial mastectomy and an immediate m.
latissimus dorsi musculocutaneous ﬂap was used to main-
tain breast shape and volume. All data were collected ret-
rospectively from the patient ﬁles. There was no structured
inquiry for pain score, cosmetic outcome, or patient
satisfaction.
Technical aspects of the operation
If feasible the operation was carried out in a side position,
allowing a simultaneous procedure by surgeon (excision)
and plastic surgeon (preparing the LD ﬂap with a skin
island). Based on physical examination, mammography,
and magnetic resonance imaging (MRI), all ﬁbrotic tissue
was removed (partial mastectomy) including the scar,
discolored skin, and at least the area of the radiotherapy
boost. If the defect was too large for reconstruction with
LD, the breast was mobilized and rotated above the pec-
toral fascia to minimize the defect as it affected the volume
of the LD. The muscle was ﬁxed with soluble stitches and a
suction drain was left in place. The LD skin island was
sutured to the breast skin intracutaneously. All patients
were treated with antibiotic prophylaxis.
Results
The patient characteristics are summarized in Table 1. All
patients were women whose average age varied between 42
and 63 years, with a mean of 51 years. Radiotherapy
(50 Gy) was administered in fractions of 2 Gy, with a
boost varying from 0 to 20 Gy. In seven patients the RIF
was located in the upper quadrants, ﬁve of them in the
lateral upper quadrant. The main complaint was pain,
sometimes combined with other symptoms like a burning
sensation or loss of sensitivity, hyperpigmentation, or
teleangiectasia. In two patients the main reason for treat-
ment was dermatitis with recurrent mastitis. The mean time
from BCT till PM and LD for RIF was 55 months (4
years), with a range of 27–89 months.
The mean size of the PM specimen was 465 cm
3
(230–750 cm
3), and the mean weight was 295 g (60–
980 g). Pathology reports of all excised tissue showed
pathological changes, conﬁrming the clinical diagnosis of
RIF. In no patients breast cancer was found. There were no
complications requiring surgical reintervention or leading
to prolonged hospital stay. The follow-up after PM and LD
was 13–113 months (mean: 46 months). One patient did
not report any improvement of her complaints after PM and
LD. This patient also suffered from multiple sclerosis and a
recent cerebrovascular event, and ultimately a mastectomy
was performed. The remaining eight patients were relieved
of their most signiﬁcant complaints. Postoperatively, none
of the patients required painkillers, in contrast to the situ-
ation before the operation in every case (Table 2). All
patients noticed signiﬁcant improvement in their breast
shape and compliance (Fig. 1).
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Persisting complaints after breast-conserving surgery fol-
lowed by radiotherapy represent a frequently reported
clinical problem [3, 4]. Usually the complaints resolve
without further treatment, but in some instances the adverse
reaction of radiotherapy results in an irreversible RIF with
associated with pain, erythema, and progressive edema or
Table 2 Partial mastectomy
and m. latissimus dorsi
reconstruction for radiation-
induced ﬁbrosis: results
a (Almost) no complaints
b Slight complaints
c No change
d Time to mastectomy
Patients Age at PM
and LD (years)
Volume
(cm
3)
Weight (g) Follow-up
(months)
Results after PM and LD
1 47 ? 60 24 Pain, hyperpigmentation
a
2 46 540 280 13 Edema,
a pain
b
3 65 360 180 47 Fibrosis, seroma
a
4 68 670 ? 110 Pain, ﬁbrosis
a
5 63 360 300 86 Pain, hyperpigmentation
a
6 39 270 160 113 Recurrent mastitis, ﬁbrosis
a
7 60 750 980 86 Dermatitis, ﬁbrosis
a
8 59 530 290 22 Pain,
b ﬁbrosis
a
9 55 230 210 25
d Fibrosis,
c pain
c
Table 1 Partial mastectomy
and m. latissimus dorsi
reconstruction for radiation-
induced ﬁbrosis: patient
characteristics
BCT breast-conserving therapy,
LD latissimus dorsi ﬂap
reconstruction, PM partial
mastectomy
a Whole breast irradiation and
boost
b Interval between BCT and PM
c The two main complaints
Patients Age at
BCT
Radiation
(Gy)
a
Quadrant Interval
(months)
b
Indication for PM
and LD
c
14 2 5 0 ? 16 Upper lateral 63 Pain, hyperpigmentation
24 4 5 0 ? 16 Upper central 33 Edema, pain
36 2 5 0 ? 15 Lower lateral 35 Fibrosis, seroma
4 63 50 Lower central 73 Pain, ﬁbrosis
55 7 5 0 ? 20 Upper lateral 68 Pain, hyperpigmentation
6 37 50 Upper lateral 27 Recurrent mastitis, ﬁbrosis
75 3 4 6 ? 20 Upper lateral 89 Dermatitis, ﬁbrosis
85 6 5 0 ? 15 Upper lateral 41 Pain, ﬁbrosis
94 9 5 0 ? 20 Upper lateral 69 Fibrosis, pain
Fig. 1 Two patients with
radiation-induced ﬁbrosis (left)
and the result after partial
mastectomy and m. latissimus
dorsi reconstruction (right)
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123ﬁbrosis, and complaints can persist for years. It is difﬁcult
to measure the degree of RIF with objective criteria.
Compliance is the relationship between the force acting
upon a tissue and transformation that is caused by that
force. One way of measuring the compliance is by palpa-
tion [10], but it is subjective, with a great interobserver
variability [11]. It is also possible to measure compliance
with a more objective noninvasive tissue compliance meter
(TCM) [12].
Common therapies consist of eliminating localized and
general aggravating factors, and controlling acute and
chronic inﬂammation with antibiotics and steroids. As
progress has been made in understanding the pathophysi-
ology of RIF lesions, different treatment strategies have
been developed in clinical practice. These consist of anti-
oxidants (vitamin-E [13], superoxide dismutase [14]),
angiotensin-converting enzyme inhibitor (Captopril [14]),
interferon-gamma [15], anti-inﬂammatory agents (Brufen
[16]) and Pentoxifylline (Trental) [17]. However, all the
studies of these strategies were performed in patients with
acute radiation morbidity and the results, if any, were
short-lived [13]. In a small randomized placebo-controlled
study a six-month treatment with alpha-tocopherol (vita-
min E) and pentoxifylline showed signiﬁcant regression of
RIF [18]; nevertheless, these results could not be conﬁrmed
by other investigators [19].
Hyperbaric oxygen therapy (HBOT) seems to be effec-
tive in the treatment of late radiation sequelae like pain,
edema, erythema, and soft tissue necrosis. The HBOT
allows tissue to be hyperoxygenated. By providing inhaled
100% oxygen under pressure, the arterial PO2PO2 is raised
ﬁve to ten times above normal, which promotes healing.
The hyperoxia stimulates ﬁbroblast proliferation and col-
lagen synthesis, which provide a matrix for angiogenesis at
a faster rate, resulting in soft tissue repair. However, no
randomized controlled trials are available to prove this
theory [20].
When all conservative treatments have failed, it is
necessary to excise the lesion extensively. A range of
therapeutic options are available from which to choose the
most reliable reconstruction technique to close the defect.
Muscle and pedicled musculocutaneous ﬂaps are reliable
grafts due to their safety, their vascular, trophic and anti-
infectious quality, and their excellent capacity of coverage.
A latissimus dorsi ﬂap can be harvested without sig-
niﬁcant risks or side effects and can be used to ﬁll a defect
after resection of the area with RIF. This approach is
known for its easy mobilization, high tissue vitality, and
good cosmesis. The complication rate is low [7]. In our
series we did not have complications while using LD
reconstructions.
In one patient the PM and LD failed to solve the com-
plaints based on RIF. In the other patients most of the
problems were signiﬁcantly improved with a mean follow-
up of almost 4 years (Table 2).
Conclusions
A small number of patients treated with breast-conserving
therapy and subsequent radiotherapy for breast cancer will
suffer from radiation-induced ﬁbrosis. Conservative treat-
ment is the treatment of choice, sometimes lacking success
at long-term follow-up. When associated problems inter-
fere with the quality of life of patients, surgical removal of
all affected tissue can help. A partial mastectomy, recon-
structed with m. latissimus dorsi proved to be a safe
treatment option with satisfying results. Eight of our nine
patients experienced improvement in associated complaints
and in the shape of the breast.
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